MRK

NYSE · Pharmaceuticals

Merck & Co. Inc.

S&P 500 Dow Jones Mega-Cap Stocks Blue Chip Stocks Pharmaceutical Stocks Healthcare Stocks Best Dividend Stocks

$115.48

+1.61 (+1.41%)

As of Jun 22, 9:30 PM ET ·

Financial Highlights (FY 2026)

Revenue

64.05B

Net Income

17.98B

Gross Margin

77.1%

Profit Margin

28.1%

Rev Growth

+3.1%

D/E Ratio

0.94

Revenue & Net Income

Margin Trends

	FY 2026	FY 2025	FY 2024	FY 2023
Gross Margin	77.1%	77.1%	60.0%	60.0%
Operating Margin	32.6%	29.4%	19.9%	18.6%
Profit Margin	28.1%	26.7%	14.5%	15.3%

Income Statement

	FY 2026	FY 2025	FY 2024	FY 2023
Revenue	64.05B	62.11B	122.92B	97.21B
Gross Profit	49.37B	47.87B	73.70B	58.29B
Operating Income	20.90B	18.25B	24.40B	18.09B
Net Income	17.98B	15.70B	17.77B	14.84B
Gross Margin	77.1%	77.1%	60.0%	60.0%
Operating Margin	32.6%	29.4%	19.9%	18.6%
Profit Margin	28.1%	26.7%	14.5%	15.3%
Rev Growth	+3.1%	+3.1%	+3.7%	+0.8%

Balance Sheet

	FY 2026	FY 2025	FY 2024	FY 2023
Total Debt	68.06B	68.06B	126.52B	165.60B
Total Equity	72.56B	72.56B	163.18B	146.99B
D/E Ratio	0.94	0.94	0.78	1.13

Cash Flow

	FY 2026	FY 2025	FY 2024	FY 2023
EBITDA	23.90B	22.02B	40.31B	27.40B
Free Cash Flow	—	—	15.03B	9.18B